Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.

@article{Behnia1999InhibitionOA,
  title={Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats.},
  author={Kamelia Behnia and Mehdi Boroujerdi},
  journal={The Journal of pharmacy and pharmacology},
  year={1999},
  volume={51 11},
  pages={1275-82}
}
Doxorubicin is an effective anticancer agent that is limited by numerous adverse effects, cardiotoxicity causing the most concern. Its alcohol metabolite, doxorubicinol, and free radicals have been implicated in the aetiology of this toxicity. This study was based on the premise that inhibition of aldo-keto reductases would improve the efficacy of doxorubicin by reducing its toxic metabolites and modifying its pharmacokinetics. We assessed the effect of in-vitro inhibition of aldo-keto… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Aldo-keto reductase 1C2 fails to metabolize doxorubicin and daunorubicin in vitro.

Drug metabolism and disposition: the biological fate of chemicals • 2008
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…